Moody's: Watson unchanged

Moody's Investors Service said that there is no impact on the ratings or outlook of Watson Pharmaceuticals, Inc. following the announcement that Watson would acquire Specifar Pharmaceuticals for $562 million.

Watson has a senior unsecured rating of Baa3 and positive outlook.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.